文献速递脊柱关节炎其他结缔组织病

中性粒细胞白细胞介素-23在脊柱关节炎谱系疾病中的作用

Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders.
PubMed 文献 · Lancet Rheumatol · 2023-01-01

本文为个人观点文章,聚焦脊柱关节炎谱系疾病中中性粒细胞炎症与MHC-I类分子关联,提出T细胞-中性粒细胞轴涉及IL-17介导的中性粒细胞募集与活化,以及活化中性粒细胞在病变部位滞留并可能放大17型T细胞反应,中性粒细胞产生IL-23和蛋白酶等反馈机制可能受局部微生物群、病原体或组织损伤调控,该轴可能解释IL-23通路阻断在某些患者中的快速起效及强直性脊柱炎患者对IL-23抑制剂无反应。

要点

  • 脊柱关节炎谱系疾病以中性粒细胞炎症为共同特征,并与MHC-I类分子强关联。
  • T细胞-中性粒细胞轴涉及IL-17介导的中性粒细胞募集与活化。
  • 活化中性粒细胞在病变部位滞留可能通过产生IL-23和蛋白酶放大17型T细胞反应。

核心结论

  • 固有免疫与适应性免疫之间的这种交互作用为屏障部位细菌和真菌微生物如何固有调控17型T细胞发育提供了新解释,并可能解释某些临床疾病特征和治疗反应,如IL-23通路阻断在某些患者中的快速起效。
  • 该轴可能对理解强直性脊柱炎患者对IL-23抑制剂无反应至关重要,因为中轴骨骼是中性粒细胞丰富的部位,也是成人髓系造血的部位。

研究设计与样本

  • 本文为个人观点(Personal View)文章,未报告系统检索范围或样本量。

主要发现

  • 中性粒细胞炎症是脊柱关节炎及相关疾病普遍存在的共同特征,表现为银屑病关节炎患者的皮肤Munro微脓肿和骨关节中性粒细胞炎症、炎症性肠病患者的肠隐窝脓肿、前葡萄膜炎患者的眼前房积脓以及白塞病患者的中性粒细胞性宏观和微观炎症。
  • 这些疾病存在强MHC-I类分子关联,被称为MHC-I类分子病,提示涉及CD8 T细胞免疫病理,但目前尚未充分了解。
  • 新出现的数据提示T细胞-中性粒细胞轴既涉及T细胞介导和IL-17介导(17型)的中性粒细胞募集与活化,也涉及活化中性粒细胞在病变部位滞留并可能直接放大17型T细胞反应。
  • 这种放大可能涉及中性粒细胞产生IL-23和蛋白酶以及其他反馈机制,这些机制可能受局部微生物群、病原体或组织损伤调控。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neutrophilic inflammation is a pervasive characteristic common to spondyloarthropathies and related disorders. This inflammation manifests as Munro's microabscesses of the skin and osteoarticular neutrophilic inflammation in patients with psoriatic arthritis, intestinal crypt abscesses in patients with inflammatory bowel disease, ocular hypopyon in anterior uveitis, and neutrophilic macroscopic and microscopic inflammation in patients with Behçet's disease. Strong MHC class I associations are seen in these diseases, which represent so-called MHC-I-opathies, and these associations indicate an involvement of CD8 T-cell immunopathology that is not yet well understood. In this Personal View, we highlight emerging data suggesting that the T-cell-neutrophil axis involves both a T-cell-mediated and interleukin (IL)-17-mediated (type 17) recruitment and activation of neutrophils, and also a sequestration of activated neutrophils at disease sites that might directly amplify type 17 T-cell responses. This amplification likely involves neutrophilic production of IL-23 and proteases as well as other feedback mechanisms that could be regulated by local microbiota, pathogens, or tissue damage. This crosstalk between innate and adaptive immunity offers a novel explanation for how bacterial and fungal microbes at barrier sites could innately control type 17 T-cell development, with the aim of restoring tissue homoeostasis, and could potentially explain features of clinical disease and treatment response, such as the fast-onset action of the IL-23 pathway blockade in certain patients. This axis could be crucial to understanding non-response to IL-23 inhibitors among patients with ankylosing spondylitis, as the axial skeleton is a site rich in neutrophils and a site of haematopoiesis with myelopoiesis in adults.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Macleod T, Bridgewood C, McGonagle D, et al. Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders. Lancet Rheumatol. 2023. PMID: 38251507. doi:10.1016/S2665-9913(22)00334-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。